Search / Trial NCT06226233

Efficacy of Juniver, a Digital Self-help Intervention, on Symptoms of Eating Disorders: A Randomised Controlled Trial

Launched by KING'S COLLEGE LONDON · Jan 17, 2024

Trial Information

Current as of December 21, 2024

Recruiting

Keywords

Eating Disorders Anorexia Nervosa Bulimia Nervosa Binge Eating Disorder Just In Time Interventions Digital Interventions Mental Health

ClinConnect Summary

This clinical trial is studying the effectiveness of a digital self-help program called Juniver, designed to help people with eating disorders such as anorexia, bulimia, and binge-eating disorder. The Juniver program is available through an iPhone app and includes three main parts: a helpful curriculum based on proven therapies, interactive tools to engage users, and support groups where participants can connect with others facing similar challenges. The goal is to see if using Juniver can improve symptoms related to eating disorders, as well as related feelings of depression and anxiety, over a period of 12 weeks.

To participate, individuals must be at least 16 years old and living in the UK or the US, and they should have a diagnosed eating disorder. It's important that participants can use an iPhone, as the program is only available on that platform. They will need to provide contact information for a healthcare professional who can be reached if there are any concerns about their safety. During the study, participants will be randomly assigned to either use the Juniver app or be placed on a waitlist for 12 weeks, after which the effects of the program will be evaluated further. This trial aims to provide valuable insights into how digital tools can support individuals struggling with eating disorders.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged 16 or over
  • Live in the UK or the US
  • Any presence and severity of any eating disorder(s): Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding and Eating Disorders (OSFED), Avoidant Restrictive Food Intake Disorder (ARFID) and Unspecified Feeding or Eating Disorder (UFED) as measured by the EDE-Q and using item-based algorithms to determine the potential presence of one of these eating disorders
  • Able to provide informed consent
  • Willing to provide full contact details including a UK or US address, phone number and email address
  • Willing to provide contact details for a health care professional with whom they are registered (e.g., a general practitioner or primary care physician) and who the study team can contact if they are concerned about their well-being.
  • Exclusion Criteria:
  • Lack of access to an iPhone - as Juniver is currently only available for use on the iPhone system.
  • Partaking in any medically-driven special diets (e.g., linked to Coeliac, Crohn's, PCOS, type 1 or type 2 diabetes) - as these individuals would require more specialist dietary advice than the Juniver program can safely provide. Individuals with these conditions who are not on special diets would be eligible to enrol.
  • Severe depression as measured by PHQ score \> 20
  • Active suicidal intent or plan
  • .- Body Mass Index (BMI) \<15
  • Emergency hospital visit or admission within the last month for an eating disorder or other mental health concern

Trial Officials

Karina Allen, PhD

Principal Investigator

King's College London

About King's College London

King's College London is a prominent research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the college leverages its extensive expertise in medicine, neuroscience, and public health to conduct rigorous studies aimed at improving patient outcomes. As a sponsor of clinical trials, King's College London prioritizes ethical standards, participant safety, and scientific integrity, fostering an environment that encourages groundbreaking research and the translation of findings into clinical practice. Through its state-of-the-art facilities and a diverse network of researchers, the institution strives to address critical health challenges and contribute to the global body of medical knowledge.

Locations

London, , United Kingdom

London, , United Kingdom

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0